VTGN
Closed
Vistagen Therapeutics Inc
3.25
0.00 (0.00%)
Last Update: 06 Sep 2024 23:00:00
Yesterday: 3.25
Day's Range: 3.235 - 3.35
Send
sign up or login to leave a comment!
When Written:
0.1265
VistaGen Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for central nervous system (CNS) diseases. The company uses its proprietary stem cell technology platform, Human Clinical Trials in a Test Tube, to discover and develop new drug candidates.
VistaGen's lead product candidate is PH94B, a novel neuroactive nasal spray for the acute treatment of social anxiety disorder (SAD). The company is also developing AV-101, an oral prodrug of 7-chloro-kynurenic acid (7-CIK), for the treatment of major depressive disorder (MDD) and neuropathic pain.
In addition to its CNS pipeline, VistaGen is also exploring the potential of its stem cell technology platform in other therapeutic areas, such as cancer and cardiovascular disease.
VistaGen is headquartered in South San Francisco, California, and was founded in 1998. The company is publicly traded on the NASDAQ stock exchange under the ticker symbol VTGN.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
VistaGen's lead product candidate is PH94B, a novel neuroactive nasal spray for the acute treatment of social anxiety disorder (SAD). The company is also developing AV-101, an oral prodrug of 7-chloro-kynurenic acid (7-CIK), for the treatment of major depressive disorder (MDD) and neuropathic pain.
In addition to its CNS pipeline, VistaGen is also exploring the potential of its stem cell technology platform in other therapeutic areas, such as cancer and cardiovascular disease.
VistaGen is headquartered in South San Francisco, California, and was founded in 1998. The company is publicly traded on the NASDAQ stock exchange under the ticker symbol VTGN.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!